A. Shaw, J. Ziemniak, S. Liu
Feb 1, 2005
Citations
0
Influential Citations
10
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Nebivolol (N) is considered to be a unique cardiovascular agent studied worldwide for the treatment of hypertension, CHF and other cardiovascular conditions owing to vascular endothelial nitric oxide stimulating capabilities and its highly selective β1‐antagonism. It is directly glucuronidated to a set of active metabolites believed to make a clinically important contribution to therapy. It is also metabolized by polymorphic CYP2D6 to active hydroxy‐moeities, which are further glucuronidated. The present study examined the steady‐state kinetics of N in extensive (EM) and poor (PM) CYP2D6 metabolizers.